N1-(4-methylpiperazine)cyanoguanidine | 19803-92-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: N1-(4-methylpiperazine)cyanoguanidine
• 英文别名: N'-cyano-4-methylpiperazine-1-carboximidamide
• CAS: 19803-92-0
• 化学式: C₇H₁₃N₅
• 分子量: 167.214
• InChiKey: NUOXTUVJMWWBOZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.7
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  68.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  N1-(4-methylpiperazine)cyanoguanidine 、 4-溴苯胺 在 盐酸 作用下， 以 水 、 正丁醇 为溶剂， 反应 18.0h， 以27%的产率得到N1-4-methylpiperazine-N5-(4-bromo)phenyl biguanide hydrochloride
  参考文献：
  名称：

  바이구아나이드 화합물 및 이의 용도

  摘要：

  This is the translation of the text you provided: This invention relates to biguanide compounds and their uses, more specifically to biguanide derivatives that exhibit excellent effects in inhibiting cancer cell proliferation, cancer metastasis, and cancer recurrence, as well as to a method for producing them and pharmaceutical compositions containing them as active ingredients.

  公开号：

  KR20210014090A

文献信息

• BIGUANIDE COMPOUNDS AND USE THEREOF
  申请人：HANALL BIOPHARMA CO., LTD.

  公开号：US20150126518A1

  公开（公告）日：2015-05-07

  The present invention relates to biguanide compounds and use thereof, more particularly, to biguanide derivatives exhibiting excellent effects for inhibition of cancer cell proliferation and inhibition of cancer metastasis and recurrence, a method for preparing the same, a pharmaceutical composition containing the same as an active ingredient, and a method of prevention or treatment of cancer comprising the step of administering an effective amount of the composition to a subject in need thereof.

  本发明涉及双胍类化合物及其使用，更具体地涉及表现出对抑制癌细胞增殖、抑制癌转移和复发具有优异效果的双胍衍生物，以及制备该化合物的方法、含有该化合物作为活性成分的药物组合物，以及包括向需要的受试者施用所述组合物的有效量的步骤的癌症预防或治疗方法。
• N1-Cyclic Amine-N5-Substituted Biguanide Derivatives, Methods of Preparing the Same and Pharmaceutical Composition Comprising the Same
  申请人：Kim Sung Wuk

  公开号：US20140179661A1

  公开（公告）日：2014-06-26

  A N1-cyclic amine-N5-substituted biguanide derivative of Formula 1 or a pharmaceutically acceptable salt thereof, a method of manufacturing the same, and a pharmaceutical composition including the biguanide derivative or the pharmaceutically acceptable salt thereof as an active ingredient are provided. The biguanide derivatives have an effect of inhibiting cancer cell proliferation and also exhibit anticancer activity including inhibition of cancer metastasis and cancer recurrence, because they are effective in activating AMPK, which is associated with the control of energy metabolism, even when administered in a small dose compared with conventional drugs. Also, the biguanide derivatives are highly effective at lowering blood glucose and lipid concentration by AMPK activation, thus they may be effectively used to treat diabetes mellitus, obesity, hyperlipemia, hypercholesterolemia, fatty liver, coronary artery disease, osteoporosis, polycystic ovary syndrome and metabolic syndrome.

  提供了一种公式1的N1-环氨基-N5-取代双胍衍生物或其药用盐，以及制造该衍生物的方法，以及包含双胍衍生物或其药用盐作为活性成分的药物组合物。这些双胍衍生物具有抑制癌细胞增殖的效果，并且还表现出抗癌活性，包括抑制癌症转移和癌症复发，因为它们在与传统药物相比仅需小剂量时，能有效激活与能量代谢控制相关的AMPK。此外，双胍衍生物通过激活AMPK在降低血糖和血脂浓度方面具有很高的效果，因此它们可能有效用于治疗糖尿病、肥胖症、高脂血症、高胆固醇血症、脂肪肝、冠状动脉疾病、骨质疏松症、多囊卵巢综合征和代谢综合征。
• N1-Cyclic Amine-N5-Substituted Phenyl Biguanide Derivatives, Methods of Preparing the Same and Pharmaceutical Composition Comprising the Same
  申请人：Kim Sung Wuk

  公开号：US20140179660A1

  公开（公告）日：2014-06-26

  An N1-cyclic amine-N5-substituted phenyl biguanide derivative of Formula 1 or a pharmaceutically acceptable salt thereof, a method of manufacturing the same, and a pharmaceutical composition including the biguanide derivative or the pharmaceutically acceptable salt thereof as an active ingredient are provided. The biguanide derivatives have an effect of inhibiting cancer cell proliferation and also exhibit anticancer activity including inhibition of cancer metastasis and cancer recurrence, because they are effective in activating AMPK, which is associated with the control of energy metabolism, even when administered in a small dose compared with conventional drugs. Also, the biguanide derivatives are highly effective at lowering blood glucose and lipid concentration by AMPK activation, thus they may be effectively used to treat diabetes mellitus, obesity, hyperlipemia, hypercholesterolemia, fatty liver, coronary artery disease, osteoporosis, polycystic ovary syndrome and metabolic syndrome.

  提供了一种Formula 1的N1-环氨基-N5-取代苯基双胍衍生物或其药用盐，以及制备该化合物的方法，以及包含该双胍衍生物或其药用盐作为活性成分的药物组合物。这些双胍衍生物具有抑制癌细胞增殖的作用，并且还表现出抗癌活性，包括抑制癌症转移和癌症复发，因为它们能够有效激活与能量代谢控制相关的AMPK，即使与传统药物相比，以小剂量给药也具有显著效果。此外，这些双胍衍生物通过激活AMPK而高效降低血糖和血脂浓度，因此它们可能有效用于治疗糖尿病、肥胖症、高脂血症、高胆固醇血症、脂肪肝、冠心病、骨质疏松症、多囊卵巢综合征和代谢综合征。
• N1-CYCLIC AMINE-N5-SUBSTITUTED BIGUANIDE DERIVATIVES, METHODS OF PREPARING THE SAME AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME
  申请人：Immunomet Therapeutics Inc.

  公开号：EP2742020B1

  公开（公告）日：2017-10-25
• N1-CYCLIC AMINE-N5-SUBSTITUTED PHENYL BIGUANIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME
  申请人：Immunomet Therapeutics Inc.

  公开号：EP2742019B1

  公开（公告）日：2021-03-03